Scienceonline - Last News

Single brain scan can diagnose Alzheimer’s disease

Single brain scan can diagnose Alzheimer’s disease

23 Giugno 2022

A single MRI scan of the brain could be enough...

Researchers create ‘time machine’ simulations studying the lifecycle of ancestor galaxy cities

Researchers create ‘time machine’ simulations studying the lifecycle of ancestor galaxy cities

06 Giugno 2022

For the first time, researchers have created simulations that directly...

Unlocking the secrets of killer whale diets and their role in climate change

Unlocking the secrets of killer whale diets and their role in climate change

20 Maggio 2022

Killer whale populations are invading the Arctic, causing significant disruptions...

New mechanism for regulating supply of DNA building blocks may lead to better antibiotics

New mechanism for regulating supply of DNA building blocks may lead to better antibiotics

19 Maggio 2022

In a new study published in Nature Communications, researchers from...

New study reveals impact of sea level rise on human groups during Mesolithic and Neolithic periods

New study reveals impact of sea level rise on human groups during Mesolithic and Neolithic periods

19 Maggio 2022

A study carried out in the area around the Pego-Oliva...

Snake-like limb loss in a Carboniferous amniote

11 Aprile 2022

Among living tetrapods, many lineages have converged on a snake-like...

Protein boosts height growth in girls

Protein boosts height growth in girls

07 Aprile 2022

Protein boosts height growth in girls. Just seven grams over...

Fungicide combo against devastating red clover disease

Fungicide combo against devastating red clover disease

07 Marzo 2022

Red clover, an important forage crop for grazing cattle, can...

Biosimilar of Costly Inflammatory Bowel Disease Therapy Found Safe and Effective

Wiley 06 Mar 2017
1877 volte

 

Treatment of Crohn's disease and ulcerative colitis has been greatly improved by the introduction of biologic therapies such as infliximab (which targets tumour necrosis factor alpha), but at considerable cost. A recent analysis of results from 11 published studies including 829 patients shows that a new and lower-cost biosimilar for infliximab-called CT-P13 (Remsima/Inflectra)-has excellent clinical efficacy and safety. Biosimilars are highly similar versions of complex biologic therapies. CT-P13 has been recently approved in the United States, the European Union, Australia, Canada, Japan, and many other countries.

"Meta-analyses of the efficacy among these studies showed that induction of clinical response in Crohn's disease and ulcerative colitis was achieved in over 70% of patients at short (8-14 weeks) and medium (24-30 weeks) terms," said Dr. Atsushi Sakurab, senior author of the Alimentary Pharmacology & Therapeutics analysis. "Analysis of safety also showed that adverse effects related to CP-T13 were rare," said lead author Dr. Yuga Komaki. "Furthermore, the pooled rates of sustained clinical responses after switching from infliximab to CT-P13 remained high at 75% to 96% through a period of 1 year." The authors noted that the results of their comprehensive analysis will help guide physicians to confidently and safely initiate or transition patients to CP-T13.

Access the paper:

http://onlinelibrary.wiley.com/doi/10.1111/apt.13990/full

Vota questo articolo
(0 Voti)

Lascia un commento

Assicurati di aver digitato tutte le informazioni richieste, evidenziate da un asterisco (*). Non è consentito codice HTML.

 

Scienzaonline con sottotitolo Sciencenew  - Periodico
Autorizzazioni del Tribunale di Roma – diffusioni:
telematica quotidiana 229/2006 del 08/06/2006
mensile per mezzo stampa 293/2003 del 07/07/2003
Scienceonline, Autorizzazione del Tribunale di Roma 228/2006 del 29/05/06
Pubblicato a Roma – Via A. De Viti de Marco, 50 – Direttore Responsabile Guido Donati

Photo Gallery